PARP Inhibitors in the Management of Ovarian Cancer
Key Points
Key Points
- These recommendations pertain only to patients with epithelial ovarian, tubal, or primary peritoneal cancer who have not previously received a poly(ADP-ribose) polymerase inhibitors (PARPi).
- The recommendations are based on clinical trial results and FDA approvals and do not necessarily capture regulatory approvals in other jurisdictions.
Treatment
...Treatmen...
...Rep...
...ecommendation 1.0Repeating PARPi therapy in...
...Newly Diagnosed Ovarian...
...on 2.0PARPi are NOT recommended for use in initia...
...apid Update – Recommendation 2.1...
...ndation 2.2The addition of olaparib to bevacizuma...
...ecommendation 2.3Inclusion of the PAR...
...Recurren...
...e – Recommendation 3.0...
...notherapy maintenance (second-line...
...treatment with niraparib for patients without germ...
...date – Recommendation 3.1/3.2PARPi...
...apid Update – Recommendation 3.3PARPi mono...
...PARPi in Comb...
Recommendation 4.0PARPi are NOT rec...
...Manag...
...ndation 5.0 Anemia...
...equiring a blood transfusion for sympto...
...ts with progressive anemia may be offered gro...
...ndation 5.1 Neutropenia...
.... Growth factor is NOT indicated for use in patie...
...openia (grade 4 lasting at least 5–7 d...
...ecommendation 5.2 Plate...
...hrombocytopenia is most common with niraparib...
...ontinue PARPi for persistent thrombocytopenia...
...5.3 Persistent cytopenia:Evaluatio...
...commendation 5.4 Nausea:...
...y patients will have tachyphylaxis of...
...ersistent nausea requiring daily anti-emetic i...
...1. PARP Inhibitors in the Management of Ovaria...
...PARPi Use Opportunities in PARPi-Na...